SCHEMBL2312424

SCHEMBL2312424

CCOC(=O)c1cc2cc(Br)ccc2nc1Cl

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.57
SMN1; SMN2 Q16637 1/20 0.57
TSHR P16473 1/20 0.53
KDM4E B2RXH2 2/20 0.52
HPGD P15428 1/20 0.52
ATM Q13315 2/20 0.47
MAPK1 P28482 1/20 0.46
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
HSP90AA1 P07900 1/20 0.46
CASP1 P29466 1/20 0.45
GAA P10253 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
RXFP1 Q9HBX9 1/20 0.45
GABRA1 P14867 1/20 0.44
GABRB1 P18505 1/20 0.44
GABRA3 P34903 1/20 0.44
GABRB2 P47870 1/20 0.44
MAPT P10636 2/20 0.44
CYP4F2 P78329 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14492426 0.89 ALDH1A1 (0.54) ALDH1A1SMN1; SMN2TSHRKDM4EHPGD
SCHEMBL2000858 0.86 TSHR (0.71) ALDH1A1SMN1; SMN2TSHRKDM4EHPGD
SCHEMBL2314666 0.86 TSHR (0.56) ALDH1A1SMN1; SMN2TSHRKDM4EHPGD
SCHEMBL7266030 0.85 L3MBTL1 (0.53) ALDH1A1SMN1; SMN2TSHRKDM4EHPGD
SCHEMBL27810492 0.84 TSHR (0.76) ALDH1A1SMN1; SMN2TSHRKDM4EHPGD
SCHEMBL30923332 0.82 ALDH1A1 (0.54) ALDH1A1SMN1; SMN2TSHRKDM4EHPGD
SCHEMBL2203793 0.82 ALDH1A1 (0.54) ALDH1A1SMN1; SMN2TSHRKDM4EHPGD
SCHEMBL29076961 0.81 KDM4E (0.57) ALDH1A1SMN1; SMN2TSHRKDM4EHPGD
SCHEMBL26617732 0.81 TSHR (0.53) ALDH1A1SMN1; SMN2TSHRKDM4EHPGD
SCHEMBL30681926 0.80 GLP1R (0.50) ALDH1A1TSHRKDM4EHPGDATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118359604-A Protein arginine methyltransferase inhibitors 华润医药研究院(深圳)有限公司 2024-07-19 CN disclosed
US-8288549-B2 Glycine B antagonist MERZ PHARMA GMBH & CO. KGAA (DE) 2012-10-16 US disclosed
US-20110190342-A1 GLYCINE B ANTAGONIST HENRICH MARKUS 2011-08-04 US disclosed
EP-2350014-A1 GLYCINE B ANTAGONISTS Merz Pharma GmbH & Co. KGaA (DE) 2011-08-03 EP disclosed
WO-2010037533-A1 GLYCINE B ANTAGONISTS MERZ PHARMA GMBH & CO KGAA (DE) 2010-04-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110190342-A1 GLYCINE B ANTAGONIST GRIN2B, GLRB, GRIN2A ALDH1A1 4071/4885SMN1; SMN2 855/4885TSHR 2793/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.